Medicine
Lecanemab Autoinjector 250 mg/1.25 mL injection
Lecanemab Autoinjector 250 mg/1.25 mL injection is a prescription medicine containing Lecanemab for subcutaneous use, marketed by Eisai, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store LEQEMBI vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not…
Key facts
- Active ingredient (INN)
- Lecanemab
- Brand
- Lecanemab Autoinjector
- Strength
- 250 mg/1.25 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 2 syringes of 1.25 mL
- Marketing authorisation holder
- Eisai
- Manufacturer
- Eisai
- Origin register
- US FDA, United States
- Storage
- Store LEQEMBI vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Subcutaneous Injection Store LEQEMBI IQLIK autoinjectors in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. If needed, the autoinjectors can be stored at room temperature up to 25°C (77°F) in the original carton for up to 14 days.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N06DX04 Lecanemab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 July 2026
- Identifiers
- RxCUI 2626147, 2626153, 2626155 +3DailyMed set ID 9d1ff786-e577-410a-a273-c4d7d0e4e975NDC 62856-222Application BLA761375
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 syringe, plastic in 1 carton / 1.25 mL in 1 syringe, plastic | 62856-222-02 | Eisai | 13 July 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Lecanemab
Clinical summary
Lecanemab is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. It is available as injection for intravenous and subcutaneous use. MedsAcross supplies Lecanemab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LecanemabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- LEQEMBI prescribing information (Eisai) · U.S. National Library of Medicine, DailyMed
- Leqembi: European public assessment report (EPAR) · European Medicines Agency
Need Lecanemab Autoinjector 250 mg/1.25 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.